Yi Sun
Associate
San Diego
yi.sun@lw.com
+1.858.523.5415
PRACTICES
- Intellectual Property Litigation
- Litigation & Trial
INDUSTRIES
- Healthcare & Life Sciences
EDUCATION
- JD, Harvard Law School, 2015
cum laude - PhD in Molecular Biology, Princeton University, 2011
- BS in Biological Sciences, Tsinghua University, 2006
LANGUAGES SPOKEN
PROFILE
Dr. Yi Sun represents clients in patent and trade secret litigation, particularly in the biotechnology, pharmaceutical, and life sciences industries.
As a patent lawyer with a doctorate in molecular biology, Yi leverages her technical and legal experience in district court and appellate actions, including litigation arising under the Hatch-Waxman Act and the Biologics Price Competition and Innovation Act (BPCIA).
Yi advises clients at all stages of litigation, including pre-suit investigation, litigation, trial, and appeal.
Before joining Latham, Yi developed substantial experience in patent prosecution, patent portfolio management, opinion practice, and advising clients on freedom-to-operate and due diligence matters. She earned her PhD in molecular biology based on her research in genetic and cell-signaling control of embryonic development of the body axes. Her undergraduate thesis involved purification and characterization of recombinant proteins using chromatography.
EXPERIENCE
Yi’s experience includes representing:
- AbbVie in:
- Multiple lawsuits under the BPCIA involving Humira®
- Hatch-Waxman litigation involving Rinvoq®
- Amgen in Hatch-Waxman litigation involving Parsabiv®
- Astellas in a suit to recover rights to confidential information and correct inventorship of patents related to human mesenchymal stem cells
- Ology Bioservices in trade secret litigation concerning plasmid manufacturing technology
- A major pharmaceutical company in Hatch-Waxman litigations involving its brand vitamin B12 nasal spray and epinephrine injection
- A branded pharmaceutical company in Hatch-Waxman litigation involving its leukemia and lymphoma chemotherapy
- A major pharmaceutical company in arbitration for licensing disputes concerning antiviral therapy
- A major pharmaceutical company in Hatch-Waxman litigation regarding its brand peptide drug for osteoporosis*
- A branded pharmaceutical company in Hatch-Waxman litigation regarding its morning sickness medication*
- An innovative pharmaceutical company in multiple Federal Circuit appeals arising from interference proceedings before the US Patent and Trade Office (USPTO) involving RNA-targeted therapeutics for muscular dystrophy*
- US and international clients in patent matters involving biotechnology and pharmaceutical products, as well as medical device, chemical engineering, mechanical, and electrical technologies*
*Matter handled prior to joining Latham